Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease
Tuesday, April 1, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses a poster presentation at the AD/PD 2025 conference, highlighting the identification of cerebrospinal fluid (CSF) proteins that correlate with cognitive outcomes in participants of the Phase 2 SHINE study. This study evaluates the effects of CT1812 in patients with Alzheimer's disease, suggesting promising implications for future treatments.
Price reaction · baseline $0.4208 (2025-03-31 close) · hit pre-market · 5 other CGTX headline(s) in the window, move may be shared
day 0 close
-6.8%
day 1
-1.9%
day 3 · peak
-15.8%
Market Sentiment Analysis
POSITIVE FACTORS
Identification of CSF proteins could enhance understanding of Alzheimer's.
The study may lead to improved cognitive outcomes for patients.
CT1812 shows potential in the treatment of Alzheimer's disease.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Lizama BN, Pandey K, Duong D, et al. Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease . Poster presented at AD/PD 2025 ; Vienna, Austria
Frequently Asked Questions
What was presented at the AD/PD 2025 conference?
The presentation focused on identifying CSF proteins correlating with cognitive outcomes in Alzheimer's patients.
What is the significance of the SHINE study?
The SHINE study evaluates the effects of CT1812 on cognitive outcomes in Alzheimer's disease.
What does CT1812 target in Alzheimer's treatment?
CT1812 aims to improve cognitive outcomes in patients with Alzheimer's disease.